Silence Therapeutics PLC

Healthcare · Biotechnology

9.50$ -3.1% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Balance Sheet

Silence Therapeutics PLC (SLN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 106 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet SLN
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	56	56	51	51	55	55	48	48	39	39	30	30	46	46	100	100	–	86	–	101	93	96	87	83	124	108	94	93	98	119	245	189	169	162	185	165	147	131	115	106
Current Assets	42	42	33	33	46	46	38	38	29	29	21	21	37	37	91	91	76	76	37	91	83	86	77	73	113	97	84	82	88	103	229	176	158	150	170	149	134	119	103	94
Cash	39	39	30	30	43	43	29	29	21	21	12	12	14	14	10	10	–	27	-37	71	71	74	59	52	90	55	47	30	59	69	143	109	62	97	65	42	82	11	5.7	72
Cash & Short-Term Investments	39	39	30	30	43	43	34	34	27	27	17	17	34	34	50	50	–	37	37	81	76	74	59	52	90	71	63	50	59	69	193	150	129	118	137	114	102	85	70	72
Receivables	0.8	0.8	0.6	3.3	–	2.0	–	4.0	–	2.4	–	3.5	0.0	0.0	33	33	34	29	6.5	0.4	3.8	0.3	2.6	2.9	0.1	0.9	1.7	12	0.5	24	24	1.7	0.3	0.8	17	20	22	25	22	9.3
Inventory	–	–	–	-3.3	–	–	–	-4.0	–	-0.4	–	–	–	-0.5	–	–	–	-24	–	–	–	0.0	–	–	–	-16	–	0.0	0.0	-19	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	–	–	0.6	0.6	0.8	0.8	1.1	1.1	1.3	1.3	1.5	1.9	1.9	1.9	2.3	2.2	–	2.0	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	7.7	7.7	7.9	7.9	8.0	8.0	8.0	8.0	8.1	8.1	8.1	8.1	7.7	7.7	8.2	8.2	–	8.1	–	7.8	7.8	7.6	7.7	7.8	8.0	8.0	8.0	7.8	7.8	10.0	9.8	7.7	7.5	7.5	9.8	11	11	11	10	10
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	–	0.0	–	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.2	0.2
Total Liabilities	1.6	1.6	2.8	2.8	2.7	2.7	3.6	3.6	3.8	3.8	2.9	2.9	25	25	72	72	–	77	-9.1	77	76	88	83	88	90	85	78	80	78	97	89	76	75	55	298	71	73	69	66	68
Current Liabilities	1.6	1.6	2.8	2.8	2.7	2.7	3.6	3.6	3.8	3.8	2.9	2.9	9.7	9.7	9.2	9.2	26	26	15	15	18	15	16	20	26	22	18	20	18	22	18	18	17	13	19	15	17	14	10	13
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	0.3	0.3	0.0	0.0	–	0.3	–	0.2	0.1	0.1	0.1	0.1	0.5	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	–	0.1	0.1	0.1	0.1
Accounts Payable	0.5	0.5	2.8	2.8	0.5	0.5	3.6	3.6	1.1	1.1	2.9	2.9	1.8	1.8	4.7	4.7	2.3	2.3	7.9	7.9	9.2	4.1	7.7	12	15	3.2	13	12	12	3.3	13	15	14	3.0	19	14	17	4.4	10	13
Shareholders' Equity	54	54	49	49	52	52	44	44	35	35	27	27	21	21	28	28	–	9.1	9.1	24	16	8.5	4.0	-4.7	34	22	17	12	20	22	156	113	95	107	-113	94	74	62	49	38
Retained Earnings	-116	-116	-122	-122	-116	-116	-125	-125	-134	-134	-141	-141	-152	-152	-163	-163	-184	-184	-204	-204	-214	-223	-231	-243	-250	-263	-272	-283	-291	-432	-386	-320	-347	-379	503	-530	-551	-563	-578	-590
Shares Outstanding	23	23	23	23	23	23	23	23	24	24	24	24	26	26	27	27	28	29	29	30	30	30	10.0	10.0	11	12	12	12	12	13	15	16	16	16	16	16	16	16	16	16

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings